Lymphomas – Related resources
06.06.2013 • Sonuncu dəyişiklik 25.07.2018
This article is created and updated by the EBMG Editorial Team
Cochrane reviews
- Adding radiotherapy to chemotherapy improves 5-year overall survival and tumour control in patients with newly diagnosed Hodgkin’s lymphoma compared to chemotherapy alone. There is no evidence that complete response rate is different between the treatment groups.
- Addition of interferon-alpha (IFN) as maintenance therapy for follicular lymphoma after or concomitant with chemotherapy may improve progression-free survival but a net benefit for overall survival is less evident and IFN is associated with significant toxicities .
- High-dose chemotherapy followed by autologous stem cell transplantation (HDT) is not more effective in improving overall survival in low-risk patients than control therapies (CT) as initial therapy for aggressive Non-Hodgkin lymphoma (NHL). Poor risk patients seem to benefit from HDT, but the evidence is insufficient .
- Prophylactic treatment with granulopoiesis-stimulating factor reduces the risk for neutropenia, febrile neutropenia and infections in patients undergoing conventional chemotherapy for malignant lymphoma, but does not improve overall survival or freedom from treatment failure .
Other evidence summaries
- Systemic therapy is effective and palliative in mycosis fungoides and Sezary syndrome .
Other Internet resources
-
Kansalliset hoitosuositukset. Suomen Lymfoomaryhmä
- Onkologiayhdistys. Lymfoomaryhmän kansainväliset hoitosuositukset
- PDQ Cancer Information Summaries. Adult non-Hodgkin lymphoma treatment .
- PDQ Cancer Information Summaries. Adult Hodgkin lymphoma treatment Hodgkin lymphoma. Orphanet ORPHA391 Non-Hodgkin lymphoma. Orphanet ORPHA547 Diffuse large B-cell lymphoma. Orphanet ORPHA544 Follicular lymphoma. Orphanet ORPHA545 Mantle cell lymphoma. Orphanet ORPHA52416
Literature
- Swerdlow SH, Campo E, Harris NL, ym.. (Eds) WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th edition. International Agency for Research on Cancer (IARC), 2008.
- Horning SJ. Risk, cure and complications in advanced hodgkin disease. Hematology Am Soc Hematol Educ Program 2007;2007():197-203.
- Radford J. Limited-stage disease: optimal use of chemotherapy and radiation treatment. Hematology Am Soc Hematol Educ Program 2008;2008():321-5.
- Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program 2007;2007():216-25.
- Savage KJ. Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program 2008;2008():280-8.
- Sweetenham JW. Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease. Hematology Am Soc Hematol Educ Program 2005;():252-9.
- Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th edition. International Agency for Research on Cancer (IARC), 2008
- Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007 May 10;25(14):1916-23.